logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Myelodysplastic Syndromes

    FiltersReset Filters
    11 results

    • azacitidine

      (AZACITIDINE)
      Eugia US LLC
      Usage: Azacitidine for injection is indicated for treating adult patients with specific myelodysplastic syndrome subtypes, including refractory anemia, refractory anemia with ringed sideroblasts (with complications), refractory anemia with excess blasts, and chronic myelomonocytic leukemia. Pediatric use is not labeled due to marketing exclusivity.

    • azacitidine

      (Azacitidine)
      Cipla USA Inc.
      Usage: Azacitidine for injection is indicated for adult patients with myelodysplastic syndromes (MDS), specifically subtypes such as refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia.

    • azacitidine

      (Azacitidine)
      Dr. Reddy's Laboratories Inc.
      Usage: Azacitidine for injection is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), specifically refractory anemia, refractory anemia with ringed sideroblasts (with certain conditions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.

    • decitabine

      (Decitabine)
      Novadoz Pharmaceuticals LLC
      Usage: Decitabine for injection is indicated for treating adult patients with myelodysplastic syndromes (MDS), including all subtypes, both previously treated and untreated, as well as chronic myelomonocytic leukemia in various risk groups according to the International Prognostic Scoring System.

    • decitabine

      (decitabine)
      Gland Pharma Limited
      Usage: Decitabine for Injection is indicated for adult patients with myelodysplastic syndromes (MDS), including all French-American-British subtypes and varying risk groups, regardless of prior treatment status.

    • grafapex

      (treosulfan)
      Medexus Pharma, Inc.
      Usage: GRAFAPEX is indicated, in combination with fludarabine, as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients aged 1 year and older with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

    • lenalidomide

      (Lenalidomide)
      Biocon Pharma Inc.
      Usage: Lenalidomide is indicated for treating multiple myeloma (MM) in combination with dexamethasone, as maintenance therapy post-autologous stem cell transplantation, and for transfusion-dependent anemia due to myelodysplastic syndromes. It's also used for relapsed mantle cell lymphoma and in combination with rituximab for follicular and marginal zone lymphomas.

    • lenalidomide

      (lenalidomide)
      Amneal Pharmaceuticals NY LLC
      Usage: Lenalidomide is indicated for the treatment of adult patients with multiple myeloma in combination with dexamethasone and as maintenance therapy post-autologous hematopoietic stem cell transplantation. It also treats transfusion-dependent anemia in adults with low- or intermediate-1-risk myelodysplastic syndromes associated with deletion 5q. Not recommended for CLL outside clinical trials.

    • lenalidomide

      (lenalidomide)
      Cipla USA Inc.
      Usage: Lenalidomide capsules are indicated for treating adult patients with multiple myeloma (in combination with dexamethasone or as maintenance therapy post-transplant), myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma (with rituximab). Not recommended for chronic lymphocytic leukemia outside clinical trials.

    • lenalidomide

      (Lenalidomide)
      Aurobindo Pharma Limited
      Usage: Lenalidomide is indicated for treating multiple myeloma in adults, both as a combination therapy with dexamethasone and as maintenance therapy post-autologous stem cell transplantation. It is also used for transfusion-dependent anemia in adults with low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality.